Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysis.

IF 2.9 3区医学 Q2 PHARMACOLOGY & PHARMACY

Pharmacotherapy Pub Date : 2024-10-23 DOI:10.1002/phar.4619

Ye-Qian He, Yu-Qing Wei, Guang-Ming Huang, Guo-Ping Liu, Zhong-Qiu Lin, Tao-Tao Liu, Xia Jiang, Jie-Jiu Lu

{"title":"Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysis.","authors":"Ye-Qian He, Yu-Qing Wei, Guang-Ming Huang, Guo-Ping Liu, Zhong-Qiu Lin, Tao-Tao Liu, Xia Jiang, Jie-Jiu Lu","doi":"10.1002/phar.4619","DOIUrl":null,"url":null,"abstract":"Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low-density lipoprotein cholesterol (LDL-C). However, sex differences in the efficacy of evolocumab remain unclear. This study aimed to investigate sex differences in the efficacy of evolocumab using real-world data.Method: Data were collected from the First Affiliated Hospital of Guangxi Medical University. A total of 416 eligible patients were selected from 1463 patients treated with evolocumab for secondary prevention. Clinical data, including individual characteristics and lipids profiles, were recorded. Propensity score matching (PSM) was used to control for potential confounders, with covariates including age, body mass index, smoking status, and diabetes. All eligible participants were propensity-matched 1:1 for female versus male with a match tolerance of 0.02. The efficacy of evolocumab in females and males was compared by PSM-adjusted analysis.Results: In the PSM analysis, a significant difference was found in the relative percentage reduction of LDL-C between females and males (-42.7% vs. -54.4%, p < 0.001). In addition, the absolute LDL-C reduction was lower in females compared to males (interquartile range: -1.5 [-2.2, -0.8] mmol/L vs. -1.9 [-2.5, -1.0] mmol/L, p = 0.018). The rate of target LDL-C attainment was lower in females than in males after treatment with evolocumab (21.6% vs. 39.8%, p = 0.009).Conclusion: These results suggest that males have a better response to evolocumab in term of LDL-C reduction compared to females.","PeriodicalId":20013,"journal":{"name":"Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/phar.4619","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low-density lipoprotein cholesterol (LDL-C). However, sex differences in the efficacy of evolocumab remain unclear. This study aimed to investigate sex differences in the efficacy of evolocumab using real-world data.

Method: Data were collected from the First Affiliated Hospital of Guangxi Medical University. A total of 416 eligible patients were selected from 1463 patients treated with evolocumab for secondary prevention. Clinical data, including individual characteristics and lipids profiles, were recorded. Propensity score matching (PSM) was used to control for potential confounders, with covariates including age, body mass index, smoking status, and diabetes. All eligible participants were propensity-matched 1:1 for female versus male with a match tolerance of 0.02. The efficacy of evolocumab in females and males was compared by PSM-adjusted analysis.

Results: In the PSM analysis, a significant difference was found in the relative percentage reduction of LDL-C between females and males (-42.7% vs. -54.4%, p < 0.001). In addition, the absolute LDL-C reduction was lower in females compared to males (interquartile range: -1.5 [-2.2, -0.8] mmol/L vs. -1.9 [-2.5, -1.0] mmol/L, p = 0.018). The rate of target LDL-C attainment was lower in females than in males after treatment with evolocumab (21.6% vs. 39.8%, p = 0.009).

Conclusion: These results suggest that males have a better response to evolocumab in term of LDL-C reduction compared to females.

查看原文本刊更多论文

Evolocumab 降低 LDL-C 反应的性别差异：倾向得分匹配分析

背景：研究表明，前蛋白转化酶亚基酶/kexin 9 型抑制剂（PCSK9i）可通过降低低密度脂蛋白胆固醇（LDL-C）改善心血管预后。然而，evolocumab疗效的性别差异仍不清楚。本研究旨在利用真实世界的数据调查依维莫司疗效的性别差异：方法：数据来自广西医科大学第一附属医院。方法：数据来自广西医科大学第一附属医院，从1463名接受evolocumab二级预防治疗的患者中筛选出416名符合条件的患者。记录临床数据，包括个体特征和血脂概况。采用倾向得分匹配法（PSM）控制潜在的混杂因素，协变量包括年龄、体重指数、吸烟状况和糖尿病。所有符合条件的参与者均按女性与男性 1:1 的比例进行倾向匹配，匹配容差为 0.02。通过PSM调整分析比较了evolocumab对女性和男性的疗效：结果：在 PSM 分析中发现，女性和男性的低密度脂蛋白胆固醇相对降低百分比存在显著差异（-42.7% vs. -54.4%，p 结论：这些结果表明，男性对低密度脂蛋白胆固醇的降低效果更好：这些结果表明，与女性相比，男性对 evolocumab 降低 LDL-C 的反应更好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacotherapy 医学-药学

CiteScore

7.80

自引率

2.40%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.